Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Philadelphia, US
Size (employees)
173 (est)
Adaptimmune was founded in 2008 and is headquartered in Philadelphia, US

Adaptimmune Office Locations

Adaptimmune has offices in Philadelphia, Milton
Philadelphia, US
Milton, GB

Adaptimmune Metrics

Adaptimmune Summary

Market capitalization

$352.5 m

Closing share price

Adaptimmune's current market capitalization is $352.5 m.

Adaptimmune Market Value History

Adaptimmune Online Presence

Adaptimmune News

Adaptimmune Company Life

You may also be interested in